報價延遲最少15分鐘:2025/11/18 09:14 EST
盤前時段
|
||||
|
9.2 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.57/--
|
|
企業價值
1.16B
|
| 資產負債 |
|
每股賬面淨值
4.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
155.84M
|
|
每股收益
0.76
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/18 09:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |
